Brian Culley is Chief Executive Officer of Lineage Cell Therapeutics, Inc. (LCTX). The company reported total compensation of $2,111,170 for fiscal year 2025.
| Salary | $691,800 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $882,970 |
| Non-equity incentive plan | $518,900 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $17,500 |
| Total | $2,111,170 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Lineage Cell Therapeutics, Inc. filed April 29, 2026, accession 0001193125-26-191556.
| Peer-group chief executive median | $2,940,524 |
|---|---|
| Difference from that median | $-829,354 |
| Percentile within the disclosed peer group | 25th |
| Peers with a disclosed figure | 7 |
Medians and percentiles are computed across the peer group Lineage Cell Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brian Culley this page | Chief Executive Officer | $2,111,170 |
| Jill Howe | Chief Financial Officer | $1,005,925 |
| George Samuel III | General Counsel and Corporate Secretary | $978,225 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Lineage Cell Therapeutics, Inc. compensation brief.
Brian Culley's compensation sits inside Lineage Cell Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Lineage Cell Therapeutics, Inc. (LCTX) compensation brief